2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
23
Ovarian Neoplasms
20
Triple Negative Breast Neoplasms
14
Neoplasms
11
Neoplasm Metastasis
9
Fallopian Tube Neoplasms
9
Pancreatic Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Glioblastoma
5
Astrocytoma
5
Stomach Neoplasms
4
Small Cell Lung Carcinoma
4
Gliosarcoma
4
Colonic Neoplasms
4
Brain Neoplasms
4
Recurrence
3
Rectal Neoplasms
3
Prostatic Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Leukemia, Myelomonocytic, Chronic
3
Leukemia, Myeloid, Acute
3
Carcinoma, Ovarian Epithelial
3
Breast Neoplasms, Male
3
Uterine Cervical Neoplasms
2
Thrombocythemia, Essential
2
Testicular Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Interventions
Doxorubicin
18
Ifosfamide
13
Radiotherapy
8
Paclitaxel
7
pazopanib
6
pembrolizumab
4
Gemcitabine
4
Filgrastim
4
Chemotherapy, Adjuvant
4
Bevacizumab
4
spartalizumab
3
durvalumab
3
Sorafenib
3
Propranolol
3
Nivolumab
3
Ipilimumab
3
Imatinib Mesylate
3
Etoposide
3
Epirubicin
3
Docetaxel
3
Carboplatin
3
trebananib
2
regorafenib
2
cixutumumab
2
cemiplimab
2
carotuximab
2
brostallicin
2
belinostat
2
balstilimab
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
veliparib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled